yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q55411384-288C2196-0B91-4D81-8B32-2AEC0EB637C6
Q55411384-288C2196-0B91-4D81-8B32-2AEC0EB637C6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55411384-288C2196-0B91-4D81-8B32-2AEC0EB637C6
SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.
P2860
Q55411384-288C2196-0B91-4D81-8B32-2AEC0EB637C6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55411384-288C2196-0B91-4D81-8B32-2AEC0EB637C6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8280e0c775dbe7ef41cdeece153ef1642731a850
P2860
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.